The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Fri, 18th Dec 2020 11:06

(Alliance News) - Synairgen PLC on Friday said its Covid-19 treatment SNG001 has been given a fast track designation by the US Food and Drug Administration.

This has enabled the respiratory drug discovery and development company based in Southampton to initiate its phase III SG018 trial in the US and shorten its review times with the FDA. Dosing is expected to start imminently in the UK, it said.

Shares in Synairgen were up 37% at 148.75 pence in London on Friday.

Synairgen said its SG018 trial has been amended with regulatory agencies and is making positive progress. It has removed the lower dose arm, "thereby reducing the number of patients required to complete the placebo-controlled trial from 900 patients to 610", changed primary endpoints to 'time to hospital discharge' and 'time to recovery', and added assessments for Long Covid-19 symptoms, where patients are unable to shake off the effects of the virus months after initially falling ill, on day 60 and 90.

Chief Executive Richard Marsden said: "With this adaptation we should be able to reduce the time taken to complete the trial, which, together with an expedited review from the FDA, could allow us to get this therapy approved for patient use in Covid-19 more rapidly. With trial sites now being set up, we anticipate dosing the first patients imminently."

In November, Synairgen reported SNG001 was shown to be "well tolerated", and patients who received the drug had greater odds of improvement and recovered more rapidly from the coronavirus.

By Zoe Wickens; zoewickens@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
6 Jan 2022 14:51

IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US

IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US

Read more
11 Nov 2021 18:36

TRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal

TRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal

Read more
11 Nov 2021 13:03

Synairgen secures patients for phase III study of Covid treatment, shares jump

(Sharecast News) - Shares in Synairgen rallied on Thursday,after the respiratory drug specialist confirmed it was starting a Phase III study into a potential Covid-19 treatment.

Read more
20 Oct 2021 11:14

IN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ

IN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ

Read more
20 Oct 2021 10:56

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

Read more
30 Sep 2021 14:42

EARNINGS UPDATES: President Energy slims loss; Jangada turns a profit

EARNINGS UPDATES: President Energy slims loss; Jangada turns a profit

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
11 Jun 2021 15:59

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 May 2021 12:02

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

Read more
24 May 2021 08:33

Synairgen drug proves effective against Covid variants in lab tests

(Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.

Read more
12 May 2021 14:26

TRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss

TRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss

Read more
30 Apr 2021 14:15

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

Read more
15 Feb 2021 11:57

Synairgen confirms start of dosing in Covid-19 trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.

Read more
15 Feb 2021 10:52

IN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study

IN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study

Read more
25 Jan 2021 19:18

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.